trending Market Intelligence /marketintelligence/en/news-insights/trending/Bi_RZyFzzi7g_LaVzq_pSw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

Pfizer Inc. has joined with San Diego-based private biotech eFFECTOR Therapeutics Inc. to develop small-molecule inhibitors of a certain protein that is activated in a number of human cancers.

The collaboration will focus on the development of small-molecule inhibitors of eukaryotic initiation factor 4E, a protein that resists certain cancer treatments and is linked to poor prediction of the disease.

Under the exclusive worldwide license and collaboration agreement, Pfizer will pay eFFECTOR $15 million upfront and up to an additional $492 million in potential development and sales milestone payments.

Additionally, eFFECTOR will receive royalties on sales of any products from the program that reaches the commercialization stage.